Personalizing Frontline ADC Selection in Metastatic Triple-Negative Breast Cancer

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss how differences among available frontline antibody-drug conjugates (ADCs) can be used to individualize treatment for patients with metastatic triple-negative breast cancer (mTNBC). The faculty emphasize that selecting an ADC extends beyond efficacy alone and should incorporate biomarker status, comorbidities, anticipated toxicity profiles, and each patient's lifestyle and treatment priorities. NP Zafman explains how pre-existing gastrointestinal, hematologic, pulmonary, or ocular conditions may influence treatment selection, while also highlighting the role of PD-L1 testing in identifying patients who may benefit from immunotherapy-based combinations. Throughout the discussion, the speakers reinforce the importance of shared decision-making by helping patients understand the potential benefits and adverse event profiles of available treatment options. They conclude by emphasizing that the availability of multiple frontline ADCs provides greater opportunity to tailor therapy to individual patient characteristics and optimize outcomes for patients with metastatic triple-negative breast cancer.